Literature DB >> 10725621

Patterns of local-regional recurrence following parotid-sparing conformal and segmental intensity-modulated radiotherapy for head and neck cancer.

L A Dawson1, Y Anzai, L Marsh, M K Martel, A Paulino, J A Ship, A Eisbruch.   

Abstract

PURPOSE: To analyze the patterns of local-regional recurrence in patients with head and neck cancer treated with parotid-sparing conformal and segmental intensity-modulated radiotherapy (IMRT). METHODS AND MATERIALS: Fifty-eight patients with head and neck cancer were treated with bilateral neck radiation (RT) using conformal or segmental IMRT techniques, while sparing a substantial portion of one parotid gland. The targets for CT-based RT planning included the gross tumor volume (GTV) (primary tumor and lymph node metastases) and the clinical target volume (CTV) (postoperative tumor bed, expansions of the GTVs and lymph node groups at risk of subclinical disease). Lymph node targets at risk of subclinical disease included the bilateral jugulodigastric and lower jugular lymph nodes, bilateral retropharyngeal lymph nodes at risk, and high jugular nodes at the base of skull in the side of the neck at highest risk (containing clinical neck metastases and/or ipsilateral to the primary tumor). The CTVs were expanded by 5 mm to yield planning target volumes (PTVs). Planning goals included coverage of all PTVs (with a minimum of 95% of the prescribed dose) and sparing of a substantial portion of the parotid gland in the side of the neck at less risk. The median RT doses to the gross tumor, the operative bed, and the subclinical disease PTVs were 70.4 Gy, 61.2 Gy, and 50.4 Gy respectively. All recurrences were defined on CT scans obtained at the time of recurrence, transferred to the pretreatment CT dataset used for RT planning, and analyzed using dose-volume histograms. The recurrences were classified as 1) "in-field," in which 95% or more of the recurrence volume (V(recur)) was within the 95% isodose; 2) "marginal," in which 20% to 95% of V(recur) was within the 95% isodose; or 3) "outside," in which less than 20% of V(recur) was within the 95% isodose.
RESULTS: With a median follow-up of 27 months (range 6 to 60 months), 10 regional recurrences, 5 local recurrences (including one noninvasive recurrence) and 1 stomal recurrence were seen in 12 patients, for a 2-year actuarial local-regional control rate of 79% (95% confidence interval 68-90%). Ten patients (80%) relapsed in-field (in areas of previous gross tumor in nine patients), and two patients developed marginal recurrences in the side of the neck at highest risk (one in the high retropharyngeal nodes/base of skull and one in the submandibular nodes). Four regional recurrences extended superior to the jugulodigastric node, in the high jugular and retropharyngeal nodes near the base of skull of the side of the neck at highest risk. Three of these were in-field, in areas that had received the dose intended for subclinical disease. No recurrences were seen in the nodes superior to the jugulodigastric nodes in the side of the neck at less risk, where RT was partially spared.
CONCLUSIONS: The majority of local-regional recurrences after conformal and segmental IMRT were "in-field," in areas judged to be at high risk at the time of RT planning, including the GTV, the operative bed, and the first echelon nodes. These findings motivate studies of dose escalation to the highest risk regions.

Entities:  

Mesh:

Year:  2000        PMID: 10725621     DOI: 10.1016/s0360-3016(99)00550-7

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  70 in total

1.  Patterns-of-failure guided biological target volume definition for head and neck cancer patients: FDG-PET and dosimetric analysis of dose escalation candidate subregions.

Authors:  Abdallah S R Mohamed; Carlos E Cardenas; Adam S Garden; Musaddiq J Awan; Crosby D Rock; Sarah A Westergaard; G Brandon Gunn; Abdelaziz M Belal; Ahmed G El-Gowily; Stephen Y Lai; David I Rosenthal; Clifton D Fuller; Michalis Aristophanous
Journal:  Radiother Oncol       Date:  2017-07-31       Impact factor: 6.280

2.  Organ sparing and clinical outcome with step-and-shoot IMRT for head and neck cancer: a mono-institutional experience.

Authors:  Rosario Mazzola; Giuseppe Ferrera; Filippo Alongi; Mariella Mannino; Boris Abbate; Teresa Cucchiara; Giuseppina Iacoviello; Francesco Sciumè; Gioacchino Di Paola; Manuela Federico; Livio Blasi; Antonio Lo Casto; Roberto Lagalla; Domenico Messana
Journal:  Radiol Med       Date:  2015-02-07       Impact factor: 3.469

Review 3.  Balancing risk and reward in target delineation for highly conformal radiotherapy in head and neck cancer.

Authors:  Avraham Eisbruch; Vincent Gregoire
Journal:  Semin Radiat Oncol       Date:  2009-01       Impact factor: 5.934

4.  The potential of helical tomotherapy in the treatment of head and neck cancer.

Authors:  Dirk Van Gestel; Dirk Verellen; Lien Van De Voorde; Bie de Ost; Geert De Kerf; Olivier Vanderveken; Carl Van Laer; Danielle Van den Weyngaert; Jan B Vermorken; Vincent Gregoire
Journal:  Oncologist       Date:  2013-05-30

5.  Is it necessary to repeat CT imaging and replanning during the course of intensity-modulated radiation therapy for locoregionally advanced nasopharyngeal carcinoma?

Authors:  Chuanben Chen; Xiang Lin; Jianji Pan; Zhaodong Fei; Lisha Chen; Penggang Bai
Journal:  Jpn J Radiol       Date:  2013-06-09       Impact factor: 2.374

6.  [Technical and methodical developments of radiation oncology from a physician's point of view].

Authors:  N Willich
Journal:  Strahlenther Onkol       Date:  2012-11       Impact factor: 3.621

7.  Locoregional recurrences after post-operative volumetric modulated arc radiotherapy (VMAT) in oral cavity cancers in a resource constrained setting: experience and lessons learned.

Authors:  S Chakraborty; V M Patil; S Babu; G Muttath; S K Thiagarajan
Journal:  Br J Radiol       Date:  2015-02-03       Impact factor: 3.039

8.  Patterns of failure in anaplastic and differentiated thyroid carcinoma treated with intensity-modulated radiotherapy.

Authors:  H Vulpe; J Y Y Kwan; A McNiven; J D Brierley; R Tsang; B Chan; D P Goldstein; L W Le; A Hope; M Giuliani
Journal:  Curr Oncol       Date:  2017-06-27       Impact factor: 3.677

9.  Eliminating radiotherapy to the contralateral retropharyngeal and high level II lymph nodes in head and neck squamous cell carcinoma is safe and improves quality of life.

Authors:  Christopher R Spencer; Hiram A Gay; Bruce H Haughey; Brian Nussenbaum; Douglas R Adkins; Tanya M Wildes; Todd A DeWees; James S Lewis; Wade L Thorstad
Journal:  Cancer       Date:  2014-08-20       Impact factor: 6.860

10.  A prognostic volumetric threshold of gross tumor volume in head and neck cancer patients treated with radiotherapy.

Authors:  Paul B Romesser; Muhammad M Qureshi; Rathan M Subramaniam; Osamu Sakai; Scharukh Jalisi; Minh T Truong
Journal:  Am J Clin Oncol       Date:  2014-04       Impact factor: 2.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.